Intravenous levodopa in hallucinating Parkinson's disease patients: High-dose challenge does not precipitate hallucinations

Neurology

Volumn 50, Issue 2, 1998, Pages 515-517

  Goetz, C G ^a   Pappert, E J ^a   Blasucci, L M ^a   Stebbins, G T ^a   Ling, Z D ^a   Nora, M V ^a   Carvey, P M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL HALLUCINATION;

EID: 0031934651     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.2.515     Document Type: Article

References (6)

1. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatr 1978;135:669-675.
2. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43: 2227-2229.
3. Meilers JD, Quinn NP, Ron MA. Psychotic and depressive symptoms in Parkinson's disease: a study of the growth hormone response to apomorphine. Br J Psychiatry 1995;167-522-526.
4. Overall J, Gorham D. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-804.
5. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982;39:789-794.
6. Pappert EJ, Burhfiend C, Lipton JW, Carvey PM. Levodopa stability in solution. Mov Disord 1996;ll:24-26.